Furin Cleavage of L2 during Papillomavirus Infection: Minimal Dependence on Cyclophilins.
Despite an abundance of evidence supporting an important role for the cleavage of minor capsid protein L2 by cellular furin, direct cleavage of capsid-associated L2 during human papillomavirus 16 (HPV16) infection remains poorly characterized. The conserved cleavage site, close to the L2 N terminus, confounds observation and quantification of the small cleavage product by SDS-PAGE. To overcome this difficulty, we increased the size shift by fusing a compact protein domain, the Propionibacterium shermanii transcarboxylase domain (PSTCD), to the N terminus of L2. The infectious PSTCD-L2 virus displayed an appreciable L2 size shift during infection of HaCaT keratinocytes. Cleavage under standard cell culture conditions rarely exceeded 35% of total L2. Cleavage levels were enhanced by the addition of exogenous furin, and the absolute levels of infection correlated to the level of L2 cleavage. Cleavage occurred on both the HaCaT cell surface and extracellular matrix (ECM). Contrary to current models, experiments on the involvement of cyclophilins revealed little, if any, role for these cellular enzymes in the modulation of furin cleavage. HPV16 L2 contains two consensus cleavage sites, Arg5 (2RHKR5) and Arg12 (9RTKR12). Mutant PSTCD-L2 viruses demonstrated that although furin can cleave either site, cleavage must occur at Arg12, as cleavage at Arg5 alone is insufficient for successful infection. Mutation of the conserved cysteine residues revealed that the Cys22-Cys28 disulfide bridge is not required for cleavage. The PSTCD-L2 virus or similar N-terminal fusions will be valuable tools to study additional cellular and viral determinants of furin cleavage.



Furin cleavage of minor capsid protein L2 during papillomavirus infection has been difficult to directly visualize and quantify, confounding efforts to study this important step of HPV infection. Fusion of a small protein domain to the N terminus greatly facilitates direct visualization of the cleavage product, revealing important characteristics of this critical process. Contrary to the current model, we found that cleavage is largely independent of cyclophilins, suggesting that cyclophilins act either in parallel to or downstream of furin to trigger exposure of a conserved N-terminal L2 epitope (RG-1) during infection. Based on this finding, we strongly caution against using L2 RG-1 epitope exposure as a convenient but indirect proxy of furin cleavage.
Department of Immunobiology, University of Arizona, Tucson, Arizona, USA.
Matthew P
MP
Bronnimann
BIO5 Institute, University of Arizona, Tucson, Arizona, USA.
Christine M
CM
Calton
Department of Molecular & Cellular Biology, University of Arizona, Tucson, Arizona, USA.
Samantha F
SF
Chiquette
Department of Cellular & Molecular Medicine, University of Arizona, Tucson, Arizona, USA.
Shuaizhi
S
Li
Department of Cellular & Molecular Medicine, University of Arizona, Tucson, Arizona, USA.
Mingfeng
M
Lu
BIO5 Institute, University of Arizona, Tucson, Arizona, USA.
Janice A
JA
Chapman
Department of Chemistry & Biochemistry, University of Arizona, Tucson, Arizona, USA.
Kristin N
KN
Bratton
Department of Chemistry & Biochemistry, University of Arizona, Tucson, Arizona, USA.
Angela M
AM
Schlegel
Department of Immunobiology, University of Arizona, Tucson, Arizona, USA skcampos@email.arizona.edu.|Department of Molecular & Cellular Biology, University of Arizona, Tucson, Arizona, USA.|Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, Arizona, USA.|BIO5 Institute, University of Arizona, Tucson, Arizona, USA.
Samuel K
SK
Campos
D000595:Amino Acid Sequence; D036022:Capsid Proteins / Q000235:genetics / Q000378:metabolism*; D021983:Cyclophilins / Q000378:metabolism*; D000939:Epitopes / Q000378:metabolism; D045683:Furin / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D052162:Human papillomavirus 16 / Q000502:physiology*; D006801:Humans; D015603:Keratinocytes / Q000166:cytology / Q000378:metabolism* / Q000821:virology; D016297:Mutagenesis, Site-Directed; D009154:Mutation / Q000235:genetics; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000378:metabolism*; D030361:Papillomavirus Infections / Q000378:metabolism* / Q000821:virology; D034741:RNA, Small Interfering / Q000235:genetics; D017386:Sequence Homology, Amino Acid; D053586:Virus Internalization
D036022:Capsid Proteins; D000939:Epitopes; C063316:L2 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D034741:RNA, Small Interfering; D045683:Furin; D021983:Cyclophilins